01877.HK
Shanghai Junshi Biosciences Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 18.22
+0.61%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.0B | 2.4B | 1.9B | 1.5B | 1.5B |
| Cost of Revenue | 740.9M | 531.0M | 410.7M | 634.4M | 526.3M |
| Gross Profit | 2.4B | 2.0B | 1.5B | 835.3M | 927.2M |
| Operating Expenses | |||||
| R&D Expense | 1.3B | 1.3B | 1.3B | 1.9B | 2.4B |
| SG&A Expense | 1.6B | 1.5B | 1.5B | 1.4B | 1.3B |
| General & Admin Expense | 138.6M | 494.4M | 523.2M | 556.8M | 578.3M |
| Selling & Marketing Expense | 251.8M | 1.1B | 984.6M | 844.4M | 715.7M |
| Other Expenses | 679.4M | 80.4M | 93.4M | (51.4M) | 47.0K |
| Total Operating Expenses | 2.8B | 3.0B | 2.9B | 3.3B | 3.7B |
| Cost and Expenses | 3.6B | 3.3B | 3.3B | 4.0B | 4.2B |
| Operating Income (EBIT) | (609.7M) | (909.4M) | (1.3B) | (2.5B) | (2.8B) |
| Non-Operating | |||||
| Interest Income | 188.8M | 31.1M | 43.6M | 99.4M | 61.0M |
| Interest Expense | 80.9M | 73.5M | 51.4M | 29.0M | 29.4M |
| Net Interest Income | 107.9M | (42.5M) | (7.7M) | 70.4M | 31.6M |
| Other Non-Op Income/Expense | 43.7M | (87.4M) | (18.7M) | (37.9M) | 76.0M |
| Non-Operating Income (excl Interest) | (7.0M) | — | (126.8M) | 8.9M | 11.8M |
| EBT (Pre-Tax Income) | (566.1M) | (995.3M) | (1.4B) | (2.5B) | (2.7B) |
| Income Tax Expense | 13.0M | (13.5M) | 22.6M | 44.0M | (93.1M) |
| Bottom Line | |||||
| Net Income | (435.9M) | (851.8M) | (1.3B) | (2.3B) | (2.4B) |
| Earnings from Cont. Ops | (579.6M) | (983.3M) | (1.4B) | (2.5B) | (2.6B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (417.4M) | (851.8M) | (1.3B) | (2.3B) | (2.4B) |
| Per Share | |||||
| Basic EPS | (HK$0.40) | (HK$0.84) | (HK$1.30) | (HK$2.32) | (HK$2.60) |
| Diluted EPS | (HK$0.40) | (HK$0.84) | (HK$1.30) | (HK$2.32) | (HK$2.60) |
| Revenue Per Share | HK$2.93 | HK$2.42 | HK$1.98 | HK$1.53 | HK$1.58 |
| Shares | |||||
| Basic Shares Outstanding | 1.0B | 1.0B | 985.3M | 984.2M | 917.5M |
| Diluted Shares Outstanding | 1.0B | 1.0B | 985.3M | 984.2M | 917.5M |
| Profitability Metrics | |||||
| EBITDA | (363.3M) | (599.4M) | (935.5M) | (2.2B) | (2.5B) |
| D&A | 307.6M | 310.0M | 276.6M | 303.2M | 242.5M |
| EBIT | (584.6M) | (909.4M) | (1.2B) | (2.5B) | (2.8B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026